{
    "clinical_study": {
        "@rank": "79112", 
        "arm_group": [
            {
                "arm_group_label": "Pre-intervention", 
                "arm_group_type": "Other", 
                "description": "Patients will act as their own controls.  Will have no hormones for 3 months"
            }, 
            {
                "arm_group_label": "Post-intervention", 
                "arm_group_type": "Experimental", 
                "description": "Ortho-cyclen (or a generic equivalent) which is Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg"
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Objective Our primary objective in this study is to evaluate satisfaction of\n      hormonal contraception in this sample of women and to evaluate the impact that this hormonal\n      contraceptive has on cystic fibrosis (CF) disease in women with regular menstrual cycles\n      accompanied by cyclic exacerbations.\n\n      We hypothesize:\n\n      1a) women with CF who perceive an overall benefit of hormonal contraception will be more\n      satisfied than women with CF who do not perceive a benefit,\n\n      1b) women with CF who have cyclic exacerbations will have decreased Pseudomonas aeruginosa\n      mucoidy conversion while using hormonal contraception,\n\n      1c) women with CF who have cyclic exacerbations will have improved patient-reported quality\n      of life indices while on hormonal contraception, and\n\n      1d) women with CF who have cyclic exacerbations will have improvement in pulmonary function\n      tests while on hormonal contraception.\n\n      Secondary Objective We plan to secondarily evaluate the cervical mucus of women with CF at\n      the time of ovulation and compare it to that of healthy controls.\n\n      We hypothesize that women with CF have ovulatory cervical mucus similar to healthy peers."
        }, 
        "brief_title": "Contraceptive Hormones and Women With Cystic Fibrosis", 
        "condition": "Cystic Fibrosis Exacerbations While on and Off Hormonal Contraception", 
        "condition_browse": {
            "mesh_term": [
                "Cystic Fibrosis", 
                "Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  female, reproductive age (18-40), cyclic CF exacerbations, regular menstrual cycles\n\n        Exclusion Criteria:\n\n          -  pregnant, desires pregnancy, contra-indication to hormonal contraception, currently\n             using hormonal contraception"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02144246", 
            "org_study_id": "819889"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pre-intervention", 
                "intervention_name": "Non-hormonal period", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Post-intervention", 
                "intervention_name": "Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Mononessa", 
                    "Sprintec", 
                    "Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Contraceptive Agents", 
                "Estradiol valerate", 
                "Estradiol 3-benzoate", 
                "Estradiol 17 beta-cypionate", 
                "Norgestimate", 
                "Norgestrel", 
                "Norgestimate, ethinyl estradiol drug combination", 
                "Estradiol", 
                "Polyestradiol phosphate", 
                "Ethinyl Estradiol", 
                "Hormones", 
                "Moxifloxacin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 22, 2014", 
        "location": {
            "contact": {
                "email": "Sarah.Traxler@uphs.upenn.edu", 
                "last_name": "Sarah A Traxler, MD", 
                "phone": "215-349-5844"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "Hospital of the University of Pennsylvania"
            }, 
            "investigator": {
                "last_name": "Sarah A Traxler, MD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Contraceptive Hormones and Women With Cystic Fibrosis: Satisfaction and Effects on Disease", 
        "overall_contact": {
            "email": "Sarah.Traxler@uphs.upenn.edu", 
            "last_name": "Sarah A Traxler, MD", 
            "phone": "215-349-5844"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Satisfaction overall", 
                "measure": "Satisfaction with contraception", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "description": "Pseudomonas mucoidy conversion Quality of life Pulmonary function", 
                "measure": "Exacerbation rate", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "description": "Satisfaction overall measured by a visual analog scale 0-10", 
                "measure": "Satisfaction with contraception", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02144246"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Pennsylvania", 
            "investigator_full_name": "Courtney Schreiber", 
            "investigator_title": "Family Planning Director", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Cervical mucus of CF patients relative to healthy controls", 
            "measure": "Cervical Mucus", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "source": "University of Pennsylvania", 
        "sponsors": {
            "collaborator": {
                "agency": "Society of Family Planning", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}